Trials / Withdrawn
WithdrawnNCT03982173
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
A Phase II Whole Exome Sequencing-based Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.
Conditions
- Metastatic Colorectal Cancer
- Triple Negative Breast Cancer
- Prostate Adenocarcinoma
- Stomach Adenocarcinoma
- Esophageal Adenocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tremelimumab | tremelimumab 75mg |
| DRUG | Durvalumab | Durvalumab 1500mg |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2024-09-01
- Completion
- 2024-12-05
- First posted
- 2019-06-11
- Last updated
- 2023-01-26
Source: ClinicalTrials.gov record NCT03982173. Inclusion in this directory is not an endorsement.